The aim of the present study is to investigate the effects of the transdermal patch on the parameters of hemostasis (blood clotting), lipid (fat), and carbohydrate (sugars) metabolism in healthy women who require contraception.
- Healthy woman requesting contraception - Normal cervical smear not requiring further follow-up - History of regular cyclic menstrual periods - Willingness to use non-hormonal contraception during the two wash-out cycles both before the start of treatment and between the two treatment periods
- Pregnancy or lactation - Obesity (Body Mass Index [BMI] > 30.0 kg/m2) - Any diseases or conditions that can compromise the function of the body systems - Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results - Any disease or condition that may worsen under hormonal treatment - Undiagnosed abnormal genital bleeding - Any medication that could result in excessive accumulation, impaired metabolism, or altered excretion of the study drug or interfere with the conduct of the study or the interpretation of the results
Dinox GmbH Berlin
Berlin, Germany, 10115
E-mail: [email protected]
Phone: Not Available
A Single-Center, Open-Label, Crossover, Randomized Study to Investigate the Impact of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-day Regimen as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (0.03mg/0.15mg) in a 21-day Regimen on Hemostatic Parameters in 30 Women Aged 18 182 35 Years Over 3 Treatment Cycles in Each Period